Key terms
About IOVA
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest IOVA news
Today
8:09am ET
Truist Financial Keeps Their Buy Rating on Iovance Biotherapeutics (IOVA)
Today
8:04am ET
Iovance Biotherapeutics (IOVA) Receives a Buy from Piper Sandler
Today
6:16am ET
Iovance Biotherapeutics Poised for Growth: Analyst Reiterates Buy Rating Amid Strong Q1 Performance and Promising Clinical Advancements
Today
5:59am ET
Iovance Biotherapeutics: A Strong Buy Amidst Positive Amtagvi Launch and Financial Stability
Today
5:46am ET
Barclays Sticks to Its Buy Rating for Iovance Biotherapeutics (IOVA)
Today
12:56am ET
Iovance Biotherapeutics: A Strong Buy on Robust Growth Potential and Early Launch Success
Yesterday
4:12pm ET
Iovance Biotherapeutics reports Q1 EPS (42c), consensus (42c)
Yesterday
1:34pm ET
Iovance Biotherapeutics options imply 12.1% move in share price post-earnings
May 02
3:50am ET
Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)
Apr 30
11:25am ET
Iovance Biotherapeutics call volume above normal and directionally bullish
Mar 29
5:12pm ET
Iovance Board Changes: McPeak Retires, Vogt Nominated
Mar 20
6:01am ET
Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Coya Therapeutics, Inc. (COYA) and Iovance Biotherapeutics (IOVA)
Mar 14
7:06am ET
Iovance Biotherapeutics (IOVA) Gets a Buy from Piper Sandler
Mar 07
9:31am ET
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), Brainsway (BWAY) and Wave Life Sciences (WVE)
Mar 07
9:11am ET
Iovance Biotherapeutics price target raised to $26 from $17 at Truist
Mar 07
12:00am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Laboratory (LH), Apellis Pharmaceuticals (APLS) and Iovance Biotherapeutics (IOVA)
Mar 05
2:25pm ET
Positive Outlook for Iovance Biotherapeutics: Buy Rating Justified by Clinical Advancements and Strong Financials
Mar 05
5:12am ET
Analysts Are Bullish on These Healthcare Stocks: BridgeBio Pharma (BBIO), Elevance Health (ELV)
Mar 04
6:38am ET
Iovance Biotherapeutics: FDA lifts partial clinical hold on IOV-LUN-202 trial
Mar 01
7:35am ET
Iovance Biotherapeutics (IOVA) Receives a Buy from Truist Financial
Mar 01
7:33am ET
Iovance Biotherapeutics price target raised to $25 from $22 at Wells Fargo
Mar 01
4:57am ET
Iovance Biotherapeutics: Strong Buy on Amtagvi Launch and Positive Growth Prospects
Mar 01
1:17am ET
Iovance Biotherapeutics: Strong Start for Amtagvi and Promising Global Expansion Underpin Buy Rating
Feb 29
11:35am ET
Iovance Biotherapeutics: A Strong Buy on Robust Financials and Promising Clinical Pipeline
Feb 29
9:20am ET
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Merit Medical Systems (MMSI)
Feb 29
8:18am ET
Stifel Nicolaus Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)
Feb 29
6:38am ET
Iovance Biotherapeutics price target raised to $22 from $18 at Barclays
Feb 29
6:31am ET
Iovance Biotherapeutics (IOVA) Gets a Buy from Barclays
Feb 29
6:27am ET
Iovance Biotherapeutics: A Strong Buy on Robust Financials and Promising Drug Pipeline
Feb 28
4:24pm ET
Iovance Biotherapeutics reports Q4 EPS (45c), consensus (43c)
Feb 28
10:25am ET
Iovance Biotherapeutics call volume above normal and directionally bullish
No recent press releases are available for IOVA
IOVA Financials
Key terms
Ad Feedback
IOVA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
IOVA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
